This week, Mount Vernon Cancer Centre (MVCC) achieved a groundbreaking milestone the first internal invivo dosimetry on a patient using Trueinvivo’s® DOSEmapper™ technology. This marks a new era in personalised radiotherapy, improving both patient safety and treatment accuracy.

For years, radiotherapy planning has relied on calculations and imaging, but direct internal dose measurement, as recommended by the International Atomic Energy Agency (IAEA), is now a reality.

By directly measuring radiation inside the body, we ensure that the tumour receives the prescribed dose while minimising unnecessary exposure to healthy organs like the bladder and rectum for prostate cancer patients. This means lower risk of complications, improving patients’ quality of life.

Clinicians can now see the actual delivered dose, reducing uncertainties and making timely adjustments. This is a game-changer for brachytherapy and can pave the way for adaptive treatment strategies.

Hospital managers, NHS decision-makers, and insurers face significant costs managing radiotherapy complications. Internal invivo dosimetry mitigates these risks by ensuring treatment accuracy from the start, potentially saving millions in long-term healthcare costs.

With MVCC leading the way, we hope this breakthrough opens the eyes of clinicians worldwide to what is now possible. This is not just research—it’s the future of safer, more cost-effective cancer treatment.

A huge thank you to the incredible teams at MVCC and TrueInvivo for making this possible. Let’s continue working towards a future where precision and patient safety go hand in hand.